Ignite Creation Date:
2025-12-25 @ 12:22 AM
Ignite Modification Date:
2026-02-22 @ 3:56 PM
Study NCT ID:
NCT05092958
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-11-17
First Post:
2021-10-22
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study
Sponsor:
National Cancer Institute (NCI)
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Advanced Bladder Urothelial Carcinoma | View |
| None | Advanced Renal Pelvis Urothelial Carcinoma | View |
| None | Advanced Ureter Urothelial Carcinoma | View |
| None | Advanced Urethral Urothelial Carcinoma | View |
| None | Metastatic Bladder Urothelial Carcinoma | View |
| None | Metastatic Renal Pelvis Urothelial Carcinoma | View |
| None | Metastatic Ureter Urothelial Carcinoma | View |
| None | Metastatic Urethral Urothelial Carcinoma | View |
| None | Stage III Bladder Cancer AJCC v8 | View |
| None | Stage III Renal Pelvis and Ureter Cancer AJCC v8 | View |
| None | Stage III Renal Pelvis Cancer AJCC v8 | View |
| None | Stage III Ureter Cancer AJCC v8 | View |
| None | Stage III Urethral Cancer AJCC v8 | View |
| None | Stage IV Bladder Cancer AJCC v8 | View |
| None | Stage IV Renal Pelvis and Ureter Cancer AJCC v8 | View |
| None | Stage IV Renal Pelvis Cancer AJCC v8 | View |
| None | Stage IV Ureter Cancer AJCC v8 | View |
| None | Stage IV Urethral Cancer AJCC v8 | View |
Keywords: